These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 27773927)

  • 1. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C; Zhang Y; Yang J; Xu Y; Deng T; Li Y; Xu S; Wang S; Wang P
    Cell Commun Signal; 2024 Jul; 22(1):355. PubMed ID: 38978049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC; Lasater EA; Zhu X; Lin KC; Stewart WK; Damon LE; Salerno S; Shah NP
    Blood; 2013 Apr; 121(16):3165-71. PubMed ID: 23430109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
    Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
    Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
    Ghiaur G; Levis M
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 14. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
    Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 18. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
    Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
    Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
    Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.